Business Context and Reporting Period
Company: Sheffield Pharmaceuticals, Inc. (Note: Input metadata referenced "Theriva Biologics," but the filing text identifies the registrant as Sheffield Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2002
Status: Development stage enterprise focused on proprietary pulmonary drug delivery technologies (Premaire and Tempo systems). The company has generated minimal revenue and sustained significant net operating losses since inception in 1986.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 | Inception to Mar 31, 2002 |
|---|---|---|---|
| Total Revenues | $0 | $180,747 | $3,140,045 |
| Net Loss | $(3,133,583) | $(1,580,410) | $(90,398,909) |
| Net Loss (Attributable to Common) | $(3,686,246) | $(2,068,185) | $(96,784,492) |
| Cash and Equivalents (End of Period) | $1,056,918 | $2,381,084 | N/A |
| Net Cash Used in Operating Activities | $(1,786,321) | $(708,273) | $(82,525,094) |
| Total Assets | $2,325,721 | N/A | N/A |
| Total Liabilities | $13,307,431 | N/A | N/A |
| Stockholders' Equity (Deficiency) | $(10,981,710) | N/A | N/A |
Debt and Liquidity: As of March 31, 2002, the company held $1.06 million in cash. Total debt included $4.0 million in long-term debt (Elan Pharma), $2.0 million in convertible promissory notes, and $2.36 million in current liabilities (primarily accounts payable and accrued liabilities).
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped to $0 from $180,747 in Q1 2001. This was due to the cessation of contract research work for partner Zambon after Sheffield regained rights to the Premaire respiratory program in late 2001.
- Expense Increase: Total expenses rose to $3.09 million from $1.80 million.
- R&D: Increased to $1.15 million (from $1.05 million) driven by development of unit-dose and steroid products.
- G&A: Surged to $1.94 million (from $0.76 million) due to higher consulting/legal fees for business development and $0.5 million in severance costs for two executive officers.
- Interest Expense: Doubled to $149,831 (from $57,849) due to interest on the $4 million Elan Pharma loan.
- Balance Sheet: Current liabilities decreased significantly from $5.53 million to $2.46 million, primarily due to the reclassification of a $4 million note payable from current to long-term debt following an amendment extending the maturity date.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states the ability to continue as a going concern through December 2002 is dependent on obtaining additional funding. The company plans to raise capital through equity/debt offerings and licensing arrangements.
- Subsequent Financing (April 2002): Shortly after the period end, the company secured $2.5 million in additional funding:
- $1.0 million from Elan exercising warrants.
- $1.0 million drawdown on an amended Elan loan (total facility increased to $5 million).
- $0.5 million final installment on a Zambon loan.
- Development Strategy:
- Premaire Respiratory: Strategy is to out-license U.S. rights to a third party in 2003. Estimated remaining funding needed is $10 million.
- Tempo Systemic: Initiated a migraine therapy program with Inhale Therapeutic Systems; estimated $3.0 million in costs for 2002.
- Risks: Significant risks include failure to secure financing, inability to commercialize technologies, regulatory delays, and potential dilution from convertible securities. The company has no material market risk exposure.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $2.5 million raised in April 2002 against the estimated $10 million needed for Premaire development and $3 million for the migraine program.
- Debt Covenants: Review the terms of the Elan and Zambon loans, specifically repayment triggers tied to licensing agreements or regulatory approvals.
- Licensing Timeline: Confirm the feasibility of the 2003 target for out-licensing Premaire U.S. rights, as this is critical for future revenue.
- Executive Turnover: Assess the impact of the Q1 2002 executive resignations and associated severance on ongoing operations.
- Preferred Stock Obligations: Review the dividend requirements and conversion terms for Series C, D, E, and F preferred stock, which contribute to the net capital deficiency.